UCB U.S. News

UCB's Global Corporate Website

Welcome to UCB in the United States

Healthcare Professionals

Patients

Investors

13 Patient-first: UCB is there to listen to patients, to not only learn more about them but also from them

Read More Share:

Jan

06 UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review

Read More Share:

Nov

14 UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients

Read More Share:

Sep

22 UCB presents latest data from generalized myasthenia gravis portfolio at AANEM meeting

Read More Share:

Jun

01 Life with MG & What I Wish For Everyone Who is Diagnosed

Read More Share:

May

27 My Commitment to the Newly Diagnosed and All People Living with Myasthenia Gravis

Read More Share:

May

10 UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis

Read More Share:

Feb

25 Recognizing Rare Disease Day Every Day – The Importance of Addressing Unmet Patient Needs

At UCB, we work 365-days-a-year to find new ways to deliver solutions, peace of mind, and opportunities to people living with severe diseases because everyone deserves to live the best life they can.

Read More Share:

Feb

04 UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results

Read More Share:

Dec

10 UCB announces positive Phase 3 results for rozanolixizumab in generalized myasthenia gravis

Read More Share:

Categories

Archives

Jan

13

Patient-first: UCB is there to listen to patients, to not only learn more about them but also from them

Jan

06

UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review

Nov

14

UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients

Sep

22

UCB presents latest data from generalized myasthenia gravis portfolio at AANEM meeting

Jun

01

Life with MG & What I Wish For Everyone Who is Diagnosed

May

27

My Commitment to the Newly Diagnosed and All People Living with Myasthenia Gravis

May

10

UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis

Feb

25

Recognizing Rare Disease Day Every Day – The Importance of Addressing Unmet Patient Needs

Feb

04

UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results

Dec

10

UCB announces positive Phase 3 results for rozanolixizumab in generalized myasthenia gravis

Choose Country

UCB in the U.S.

Innovation

Disease Areas

Sustainability

Newsroom

Contact

Categories

Archives

Jan

13

Patient-first: UCB is there to listen to patients, to not only learn more about them but also from them

Jan

06

UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review

Nov

14

UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients

Sep

22

UCB presents latest data from generalized myasthenia gravis portfolio at AANEM meeting

Jun

01

Life with MG & What I Wish For Everyone Who is Diagnosed

May

27

My Commitment to the Newly Diagnosed and All People Living with Myasthenia Gravis

May

10

UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis

Feb

25

Recognizing Rare Disease Day Every Day – The Importance of Addressing Unmet Patient Needs

Feb

04

UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results

Dec

10

UCB announces positive Phase 3 results for rozanolixizumab in generalized myasthenia gravis

Choose Country

UCB in the U.S.

Innovation

Disease Areas

UCB Worldwide

Sustainability

Newsroom

Contact